2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects
Completed
Celgene
Phase 1
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single oral
dose of CC-220 and to explore the effect of food on the bioavailability of CC-220 in healthy
subjects
2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects
Completed
Celgene Corporation
Phase 1
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single oral
dose of CC-220 and to explore the effect of food on the bioavailability of CC-220 in healthy
subjects
3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule
Completed
Celgene Corporation
Phase 1
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses
of CC-220 in healthy subjects and to evaluate the relative bioavailability of a formulated
CC-220 capsule
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
Completed
Celgene
Phase 2
The purpose of this study is to determine whether CC-220 is effective for the treatment of
skin, joint and serological manifestations of systemic lupus erythematosus.
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
Completed
Celgene Corporation
Phase 2
The purpose of this study is to determine whether CC-220 is effective for the treatment of
skin, joint and serological manifestations of systemic lupus erythematosus.
This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy
of oral CC-220 in adult subjects with chronic cutaneous sarcoidosis.
This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy
of oral CC-220 in adult subjects with chronic cutaneous sarcoidosis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
